2.19
-1.35%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hua Medicine
Its shares trade on HKEX under the ticker 2552.HK. It has been listed since 14 September 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥559.1m and net income of CN¥1.25bn. At that date it held total assets of CN¥1.71bn and shareholders' equity of CN¥1.17bn.
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Sept 2018
- Employees
- 168
Leadership
Pay as last reported
- Mr. Robert NelsenNon-Executive Chairman of the Board
- Dr. Li ChenChief Executive Officer, Founder, Executive Director, since 2010CN¥17.1m
- Mr. Chien Cheng LinExecutive Vice President, Chief Strategy Officer, Executive Director, since 2017CN¥7.2m
- Dr. Yi ZhangSenior Vice President - Pharma Development, Chief Medical Officer, Executive Director, since 2018
- Dr. Jin SheSenior Vice President - Chemical Manufacturing Control Department, Chief Manufacturing Officer
- Dr. Fuxing TangChief Technology Officer, Vice President - Chemical Manufacturing Control Department, Head of Research and Development - USA
- Dr. Changhong LiChief Scientific Officer
- Mr. Qing DongVice President - Pharmaceutical Commercialization Division
- Mr. Ying XieVice President - Quality Assurance Division, Chief Quality Officer
- Dr. Zhang YiExecutive Director, since 2024
- Ms. Wing Yan YuenCompany Secretary
- Dr. Fangxin LiNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 64
- Social
- 38
- Governance
- 47
- Direct emissions (scope 1)
- 1,671,996 t
- Energy emissions (scope 2)
- 267,231 t
- Value chain emissions (scope 3)
- 1,075 t
- Women in the workforce
- 19.5%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hua Medicine has a strong focus on research and development, allowing them to develop innovative solutions and stay at the forefront of the industry.
- Hua Medicine offers a diverse product portfolio, catering to various medical needs and expanding their market reach.
Weaknesses
- Hua Medicine's market presence is relatively limited compared to some of its competitors, which may pose challenges in terms of market penetration and brand recognition.
- Hua Medicine heavily relies on collaborations and partnerships for various aspects of their business, which could introduce uncertainties and potential conflicts of interest.
Opportunities
- The pharmaceutical industry is expected to experience significant growth, presenting opportunities for Hua Medicine to expand their market share and increase revenue.
- Hua Medicine has the potential to develop new products that target emerging medical needs, opening doors for competitive advantages and increased profits.
Threats
- The pharmaceutical industry is highly competitive, and Hua Medicine faces the risk of losing market share to established competitors and new entrants.
- Hua Medicine operates in a heavily regulated industry, making it susceptible to changing regulations and potential obstacles in obtaining necessary approvals and licenses.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.